Current status and future perspectives for yttrium-90 (90Y)-ibritumomab tiuxetan in stem cell transplantation for non-Hodgkin's lymphoma
IGEV regimen and a fixed dose of lenograstim: an effective mobilization regimen in pretreated Hodgkin's lymphoma patients
Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation
Lack of CD56 expression on myeloma cells is not a marker for poor prognosis in patients treated by high-dose chemotherapy and is associated with translocation t(11;14)
The impact of histologic grade on the outcome of high-dose therapy and autologous stem cell transplantation for follicular lymphoma
High-dose chemotherapy with peripheral blood progenitor cell support for patients with non-small cell lung cancer: the experience of the European Group for Bone Marrow Transplantation (EBMT) Solid Tumours Working Party
High rate of discordance between clinical and autopsy diagnoses in blood and marrow transplantation
Risk factors for fatal infectious complications developing late after allogeneic stem cell transplantation
The occurrence of adverse events during the infusion of autologous peripheral blood stem cells is related to the number of granulocytes in the leukapheresis product
Anti-leukaemic role of acute GvHD after unrelated haematopoietic stem cell transplantation in intermediate- to high-risk acute myelogenous leukaemia
Terminology and labeling of cellular products: 1. Standards
Terminology and labeling of cellular products-2: Implementation plan
Thiotepa-based reduced intensity conditioning regimen: a 10 year follow up
Central nervous system graft-versus-host disease: consider progressive multifocal leukoencephalopathy among the differential diagnoses
Central nervous system graft-versus-host disease: consider progressive multifocal leukoencephalopathy among the differential diagnoses